The Newsroom

Investigations  /  10.02.2019

Investigation of Aptinyx Inc.

Aptinyx Inc. (APTX)’s Drug Fails to Meet Primary Endpoint

On January 16, 2019, Aptinyx announced that its drug, NYX-2925, did not achieve statistically significant separation from the placebo on a primary end point in its phase 2 trial. On this news, shares of Aptinyx fell $11.85, or 67%, to close at $5.98. The stock has yet to recover and currently trades at around $3.50, a 78% decline from its IPO price.

Aptinyx Inc. (APTX) Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can send us a message via the Shareholder Information form below.

Shareholder Information

  • Please Note: Neither the submission to nor the receipt of information by Robbins LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

Please Note: Neither the submission to nor the receipt of information by Robbins Arroyo LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

How can we help you?

CONTACT US TODAY | 1 800 350 6003 or [email protected]

Tell us your concerns